Actively Recruiting
Evaluating Safety and Tolerability of Pumitamig Alone or with Ipilimumab in Advanced or Unresectable Hepatocellular Carcinoma
Led by Bristol-Myers Squibb · Updated on 2026-10-23
198
Participants Needed
67
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of Pumitamig alone or combined with Ipilimumab in people with first-line advanced or unresectable Hepatocellular Carcinoma HCC, a type of liver cancer. This is a randomized, open-label Phase 12 study sponsored by Bristol-Myers Squibb, aiming to assess how these treatments work and their side effects in participants who have not received prior systemic therapy for advanced HCC. Participants will receive specified doses of Pumitamig or a combination of Pumitamig and Ipilimumab according to their assigned study group. The treatments are administered on specified days, and the study includes several cohorts to evaluate different dosing strategies. The study monitors participants up to approximately 25 weeks for adverse events and up to 48 weeks for tumor response, with longer-term follow-up up to 5 years for immune response and survival outcomes. Throughout the study, participants will undergo assessments including evaluation of adverse events, laboratory tests, and tumor measurements using RECIST v1.1 criteria. Researchers will track safety outcomes such as serious adverse events and dose-limiting toxicities, as well as effectiveness measures like objective response and progression-free survival. Participants health status and response to treatment will be monitored regularly during treatment and follow-up periods, which may last up to several years after treatment initiation.
CONDITIONS
Brief Title
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here